PET imaging of amyloid deposition in patients with mild cognitive impairment

It is of great clinical value to identify subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography (PET) tracer PIB showed a robust difference in retention in the brain between AD patients and healthy controls (HC). Twenty-one patients diagnosed wit...

Full description

Saved in:

Bibliographic Details
Published in	Neurobiology of aging Vol. 29; no. 10; pp. 1456 - 1465
Main Authors	Forsberg, Anton, Engler, Henry, Almkvist, Ove, Blomquist, Gunnar, Hagman, Göran, Wall, Anders, Ringheim, Anna, Långström, Bengt, Nordberg, Agneta
Format	Journal Article
Language	English
Published	United States Elsevier Inc 01.10.2008
Subjects	Aged Aged, 80 and over Aging - metabolism Aging - pathology Alzheimer Disease - diagnostic imaging Alzheimer Disease - pathology Alzheimer Disease - physiopathology Amyloid Amyloid beta-Peptides - metabolism Benzothiazoles Cerebral Cortex - diagnostic imaging Cerebral Cortex - pathology Cerebral Cortex - physiopathology Cognition Disorders - diagnostic imaging Cognition Disorders - pathology Cognition Disorders - physiopathology Converters CSF biomarkers Disease Progression FDG Female Fluorodeoxyglucose F18 Glucose - metabolism Humans Internal Medicine Male MEDICIN MEDICINE Middle Aged Mild cognitive impairment Neurology Neuropsychological Tests PET PIB Plaque, Amyloid - diagnostic imaging Plaque, Amyloid - metabolism Plaque, Amyloid - pathology Positron-Emission Tomography Predictive Value of Tests Prognosis Psychology Psykologi SAMHÄLLSVETENSKAP SOCIAL SCIENCES Socialvetenskap Mild cognitive impairment Converters PIB FDG Amyloid CSF biomarkers PET
Online Access	Get full text

Cover

Loading…

Abstract	It is of great clinical value to identify subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography (PET) tracer PIB showed a robust difference in retention in the brain between AD patients and healthy controls (HC). Twenty-one patients diagnosed with MCI (mean age 63.3 ± 7.8 (S.D.) years) underwent PET studies with 11C-PIB, and 18F-fluoro-deoxy-glucose (FDG) to measure cerebral glucose metabolism, as well as assessment of cognitive function and CSF sampling. Reference group data from 27 AD patients and 6 healthy controls, respectively, were used for comparison. The mean cortical PIB retention for the MCI patients was intermediate compared to HC and AD. Seven MCI patients that later at clinical follow-up converted to AD (8.1 ± 6.0 (S.D.) months) showed significant higher PIB retention compared to non-converting MCI patients and HC, respectively ( ps < 0.01). The PIB retention in MCI converters was comparable to AD patients ( p > 0.01). Correlations were observed in the MCI patients between PIB retention and CSF Aβ 1-42, total Tau and episodic memory, respectively.
AbstractList	It is of great clinical value to identify subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography (PET) tracer PIB showed a robust difference in retention in the brain between AD patients and healthy controls (HC). Twenty-one patients diagnosed with MCI (mean age 63.3 ± 7.8 (S.D.) years) underwent PET studies with 11C-PIB, and 18F-fluoro-deoxy-glucose (FDG) to measure cerebral glucose metabolism, as well as assessment of cognitive function and CSF sampling. Reference group data from 27 AD patients and 6 healthy controls, respectively, were used for comparison. The mean cortical PIB retention for the MCI patients was intermediate compared to HC and AD. Seven MCI patients that later at clinical follow-up converted to AD (8.1 ± 6.0 (S.D.) months) showed significant higher PIB retention compared to non-converting MCI patients and HC, respectively ( ps < 0.01). The PIB retention in MCI converters was comparable to AD patients ( p > 0.01). Correlations were observed in the MCI patients between PIB retention and CSF Aβ 1-42, total Tau and episodic memory, respectively. It is of great clinical value to identify subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography (PET) tracer PIB showed a robust difference in retention in the brain between AD patients and healthy controls (HC). Twenty-one patients diagnosed with MCI (mean age 63.3+/-7.8 (S.D.) years) underwent PET studies with (11)C-PIB, and (18)F-fluoro-deoxy-glucose (FDG) to measure cerebral glucose metabolism, as well as assessment of cognitive function and CSF sampling. Reference group data from 27 AD patients and 6 healthy controls, respectively, were used for comparison. The mean cortical PIB retention for the MCI patients was intermediate compared to HC and AD. Seven MCI patients that later at clinical follow-up converted to AD (8.1+/-6.0 (S.D.) months) showed significant higher PIB retention compared to non-converting MCI patients and HC, respectively (ps<0.01). The PIB retention in MCI converters was comparable to AD patients (p>0.01). Correlations were observed in the MCI patients between PIB retention and CSF Abeta(1-42), total Tau and episodic memory, respectively. mild cognitive impairment, converters, amyloid, PET, PIB, FDG, CSF biomarkers/k It is of great clinical value to identify Subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography (PET) tracer PIB showed a robust difference in retention in the brain between AD patients and healthy controls (HC). Twenty-one patients diagnosed with MCI (mean age 63.3 +/- 7.8 (S.D.) years) Underwent PET Studies with C-11-PIB, and F-18-fluoro-deoxy-glucose (FDG) to measure cerebral glucose metabolism, its well as assessment of cognitive function and CSF sampling. Reference group data from 27 AD patients and 6 healthy controls, respectively. were Used for comparison. The mean cortical PIB retention for the MCI patients was intermediate compared to HC and AD. Seven MCI patients that later Lit clinical follow-up converted to AD (8.1 +/- 6.0 (S.D.) months) showed significant higher PI B retention compared to non-converting MCI patients and HC, respcctively (ps < , 0.01). The PIB retention in MCI converters was comparable to AD patients (p > , 0.01). Correlations were observed in the MCI patients between PI B retention and CSF A beta(1-42). total Tau and episodic memory, respectively. It is of great clinical value to identify subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography (PET) tracer PIB showed a robust difference in retention in the brain between AD patients and healthy controls (HC). Twenty-one patients diagnosed with MCI (mean age 63.3+/-7.8 (S.D.) years) underwent PET studies with (11)C-PIB, and (18)F-fluoro-deoxy-glucose (FDG) to measure cerebral glucose metabolism, as well as assessment of cognitive function and CSF sampling. Reference group data from 27 AD patients and 6 healthy controls, respectively, were used for comparison. The mean cortical PIB retention for the MCI patients was intermediate compared to HC and AD. Seven MCI patients that later at clinical follow-up converted to AD (8.1+/-6.0 (S.D.) months) showed significant higher PIB retention compared to non-converting MCI patients and HC, respectively (ps<0.01). The PIB retention in MCI converters was comparable to AD patients (p>0.01). Correlations were observed in the MCI patients between PIB retention and CSF Abeta(1-42), total Tau and episodic memory, respectively.It is of great clinical value to identify subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography (PET) tracer PIB showed a robust difference in retention in the brain between AD patients and healthy controls (HC). Twenty-one patients diagnosed with MCI (mean age 63.3+/-7.8 (S.D.) years) underwent PET studies with (11)C-PIB, and (18)F-fluoro-deoxy-glucose (FDG) to measure cerebral glucose metabolism, as well as assessment of cognitive function and CSF sampling. Reference group data from 27 AD patients and 6 healthy controls, respectively, were used for comparison. The mean cortical PIB retention for the MCI patients was intermediate compared to HC and AD. Seven MCI patients that later at clinical follow-up converted to AD (8.1+/-6.0 (S.D.) months) showed significant higher PIB retention compared to non-converting MCI patients and HC, respectively (ps<0.01). The PIB retention in MCI converters was comparable to AD patients (p>0.01). Correlations were observed in the MCI patients between PIB retention and CSF Abeta(1-42), total Tau and episodic memory, respectively. Abstract It is of great clinical value to identify subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography (PET) tracer PIB showed a robust difference in retention in the brain between AD patients and healthy controls (HC). Twenty-one patients diagnosed with MCI (mean age 63.3 ± 7.8 (S.D.) years) underwent PET studies with11 C-PIB, and18 F-fluoro-deoxy-glucose (FDG) to measure cerebral glucose metabolism, as well as assessment of cognitive function and CSF sampling. Reference group data from 27 AD patients and 6 healthy controls, respectively, were used for comparison. The mean cortical PIB retention for the MCI patients was intermediate compared to HC and AD. Seven MCI patients that later at clinical follow-up converted to AD (8.1 ± 6.0 (S.D.) months) showed significant higher PIB retention compared to non-converting MCI patients and HC, respectively ( p s < 0.01). The PIB retention in MCI converters was comparable to AD patients ( p > 0.01). Correlations were observed in the MCI patients between PIB retention and CSF Aβ1-42 , total Tau and episodic memory, respectively. It is of great clinical value to identify subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography (PET) tracer PIB showed a robust difference in retention in the brain between AD patients and healthy controls (HC). Twenty-one patients diagnosed with MCI (mean age 63.3 ± 7.8 (S.D.) years) underwent PET studies with 11C-PIB, and 18F-fluoro-deoxy-glucose (FDG) to measure cerebral glucose metabolism, as well as assessment of cognitive function and CSF sampling. Reference group data from 27 AD patients and 6 healthy controls, respectively, were used for comparison. The mean cortical PIB retention for the MCI patients was intermediate compared to HC and AD. Seven MCI patients that later at clinical follow-up converted to AD (8.1 ± 6.0 (S.D.) months) showed significant higher PIB retention compared to non-converting MCI patients and HC, respectively (ps < 0.01). The PIB retention in MCI converters was comparable to AD patients (p > 0.01). Correlations were observed in the MCI patients between PIB retention and CSF Aβ1-42, total Tau and episodic memory, respectively.
Author	Långström, Bengt Blomquist, Gunnar Almkvist, Ove Ringheim, Anna Engler, Henry Hagman, Göran Wall, Anders Forsberg, Anton Nordberg, Agneta
Author_xml	– sequence: 1 givenname: Anton surname: Forsberg fullname: Forsberg, Anton organization: Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden – sequence: 2 givenname: Henry surname: Engler fullname: Engler, Henry organization: Department of Nuclear Medicine, Uppsala University Hospital, Uppsala, Sweden – sequence: 3 givenname: Ove surname: Almkvist fullname: Almkvist, Ove organization: Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden – sequence: 4 givenname: Gunnar surname: Blomquist fullname: Blomquist, Gunnar organization: Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden – sequence: 5 givenname: Göran surname: Hagman fullname: Hagman, Göran organization: Department of Geriatric Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden – sequence: 6 givenname: Anders surname: Wall fullname: Wall, Anders organization: Uppsala Imanet AB, Imanet, GE Healthcare, Sweden – sequence: 7 givenname: Anna surname: Ringheim fullname: Ringheim, Anna organization: Uppsala Imanet AB, Imanet, GE Healthcare, Sweden – sequence: 8 givenname: Bengt surname: Långström fullname: Långström, Bengt organization: Uppsala Imanet AB, Imanet, GE Healthcare, Sweden – sequence: 9 givenname: Agneta surname: Nordberg fullname: Nordberg, Agneta email: Agneta.K.Nordberg@ki.se organization: Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/17499392$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-17377$$DView record from Swedish Publication Index https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-109078$$DView record from Swedish Publication Index http://kipublications.ki.se/Default.aspx?queryparsed=id:117547617$$DView record from Swedish Publication Index
BookMark	eNqNkl2L1DAUhoOsuLOrf0F6Id5ox5OmbRqQhXU_VBhQcBDvQiY9HTPbJjVpd5l_b-qMiguLc5WQ85yHE95zQo6ss0jICwpzCrR8s5lbHL1bGdeqtbHreQbA58DmkIlHZEaLokppLvgRmQEVPM2LCo7JSQgbiGDOyyfkmPJcCCayGVl8vlompvtlSlyTqG7bOlMnNfYumME4mxib9GowaIeQ3Jnhe9KZtk60W9tYv8XY3Svju1h_Sh43qg34bH-ekuX11fLiQ7r49P7jxfki1SWlQ5rzhjVZobKC6RyRZhp4pXSDQLFRrMS6yptaKC0q2hS8BM2wpMUKaq4QkJ2SdKcNd9iPK9n7-AG_lU4ZuX-6iTeUBQdaZJF__SB_ab6eS-fXchwlBREHifir_-Mh4pxxHumXO7r37seIYZCdCRrbVll0Y5ClyJkoxTTF8z04rjqs_2h_ZxGBtztAexeCx-YvAnKKXm7kv9HLKXoJTMboY_u7e-3aDGpKcPDKtIdKrncSjPHdGvQy6Ji8xtp41IOsnTlUdHZPpFtjjVbtDW4xbNzobVwRSWXIJMgv06pOmwocgDLxLQouHxYcPsdPj8QFkg
CitedBy_id	crossref_primary_10_1007_s00401_011_0798_y crossref_primary_10_1212_WNL_0b013e318245f447 crossref_primary_10_1007_s00401_012_1051_z crossref_primary_10_1039_c1cp22283j crossref_primary_10_1016_j_tins_2011_05_005 crossref_primary_10_1016_j_neurobiolaging_2012_12_028 crossref_primary_10_1136_postgradmedj_2015_133759 crossref_primary_10_1016_j_neurobiolaging_2011_09_006 crossref_primary_10_1016_j_neuroimage_2010_05_068 crossref_primary_10_1111_j_1749_6632_2009_05062_x crossref_primary_10_1007_s11682_009_9067_2 crossref_primary_10_1186_s13195_021_00862_z crossref_primary_10_1212_WNL_0000000000002081 crossref_primary_10_1007_s12035_011_8228_7 crossref_primary_10_1039_d0pp00214c crossref_primary_10_1097_JGP_0b013e3181cdecf1 crossref_primary_10_1073_pnas_0914141107 crossref_primary_10_1038_s41380_024_02709_z crossref_primary_10_1007_s11065_009_9118_x crossref_primary_10_1001_jamaneurol_2018_0894 crossref_primary_10_1016_j_nicl_2013_03_014 crossref_primary_10_1089_brain_2020_0808 crossref_primary_10_1016_j_neuroimage_2014_04_015 crossref_primary_10_1002_gps_2640 crossref_primary_10_3233_ADR_170013 crossref_primary_10_1097_MNM_0000000000001004 crossref_primary_10_1002_jnr_23778 crossref_primary_10_3233_JAD_132474 crossref_primary_10_1016_j_neubiorev_2014_11_010 crossref_primary_10_31887_DCNS_2009_11_2_cqiu crossref_primary_10_1016_j_remn_2015_09_008 crossref_primary_10_1002_ana_22248 crossref_primary_10_1016_j_jocn_2017_05_008 crossref_primary_10_3233_JAD_190220 crossref_primary_10_1371_journal_pone_0076523 crossref_primary_10_1093_brain_awn320 crossref_primary_10_1111_joim_12959 crossref_primary_10_1016_j_pneurobio_2011_04_006 crossref_primary_10_1007_s00415_019_09315_y crossref_primary_10_1002_sam_11679 crossref_primary_10_1093_brain_aww160 crossref_primary_10_1007_s00401_013_1185_7 crossref_primary_10_1371_journal_pone_0066877 crossref_primary_10_3233_JAD_143006 crossref_primary_10_5692_clinicalneurol_48_467 crossref_primary_10_1016_j_nucmedbio_2010_02_003 crossref_primary_10_4103_0972_2327_74256 crossref_primary_10_1016_S1474_4422_16_00062_4 crossref_primary_10_1016_j_jns_2014_07_015 crossref_primary_10_1016_j_arr_2016_01_004 crossref_primary_10_1016_j_neurobiolaging_2012_03_002 crossref_primary_10_3390_diagnostics14242837 crossref_primary_10_1016_j_arr_2016_01_005 crossref_primary_10_1053_j_semnuclmed_2023_03_004 crossref_primary_10_1136_bmj_n156 crossref_primary_10_1038_nrneurol_2018_9 crossref_primary_10_1007_s00415_012_6428_3 crossref_primary_10_1016_j_maturitas_2016_11_018 crossref_primary_10_2217_nmt_12_75 crossref_primary_10_1007_s00259_015_3222_3 crossref_primary_10_1016_j_mednuc_2016_08_001 crossref_primary_10_1002_hbm_21153 crossref_primary_10_1523_JNEUROSCI_3669_09_2009 crossref_primary_10_1093_cercor_bhr271 crossref_primary_10_3233_JAD_160722 crossref_primary_10_1111_ggi_12991 crossref_primary_10_1016_j_neulet_2012_02_008 crossref_primary_10_1007_s00702_017_1820_x crossref_primary_10_1016_j_neuint_2008_12_016 crossref_primary_10_1016_j_neurobiolaging_2011_01_003 crossref_primary_10_1016_j_ejrad_2017_07_014 crossref_primary_10_1371_journal_pone_0047905 crossref_primary_10_1016_j_neurobiolaging_2013_05_030 crossref_primary_10_1016_j_jfma_2018_12_001 crossref_primary_10_1007_s40336_015_0100_8 crossref_primary_10_1016_j_neurobiolaging_2015_08_016 crossref_primary_10_3233_JAD_210593 crossref_primary_10_3389_fnagi_2022_785495 crossref_primary_10_1002_ana_21598 crossref_primary_10_1523_JNEUROSCI_3579_13_2014 crossref_primary_10_1016_j_tips_2015_03_002 crossref_primary_10_1016_j_media_2023_102913 crossref_primary_10_1007_s00259_011_1895_9 crossref_primary_10_1007_s40336_013_0042_y crossref_primary_10_1016_j_maturitas_2009_12_006 crossref_primary_10_3389_fnins_2019_00642 crossref_primary_10_1016_j_cpet_2009_01_003 crossref_primary_10_1039_D2RA00614F crossref_primary_10_1016_j_mednuc_2013_03_043 crossref_primary_10_31887_DCNS_2009_11_2_pscheltens crossref_primary_10_1100_2012_712048 crossref_primary_10_1016_j_arr_2021_101544 crossref_primary_10_1259_bjr_63830887 crossref_primary_10_1146_annurev_clinpsy_050212_185535 crossref_primary_10_1002_trc2_12269 crossref_primary_10_1017_S0959259812000160 crossref_primary_10_1111_j_1749_6632_2011_06015_x crossref_primary_10_1002_jmri_29070 crossref_primary_10_1016_S1474_4422_11_70123_5 crossref_primary_10_3233_JAD_220294 crossref_primary_10_1016_j_rbp_2012_07_002 crossref_primary_10_1039_C8NR03220C crossref_primary_10_1001_jamanetworkopen_2020_27472 crossref_primary_10_1016_j_nbd_2008_10_003 crossref_primary_10_1016_j_neuroimage_2014_05_027 crossref_primary_10_1186_s13550_017_0273_4 crossref_primary_10_1016_j_jalz_2010_08_230 crossref_primary_10_1016_j_neurobiolaging_2020_06_007 crossref_primary_10_3390_jimaging4050070 crossref_primary_10_1016_j_dadm_2018_09_002 crossref_primary_10_1016_j_cca_2019_02_005 crossref_primary_10_2967_jnumed_111_094029 crossref_primary_10_1002_ana_23797 crossref_primary_10_2967_jnumed_110_076315 crossref_primary_10_1111_j_1742_1241_2011_02845_x crossref_primary_10_1093_cercor_bhx294 crossref_primary_10_1515_CCLM_2011_087 crossref_primary_10_1016_j_nicl_2019_102097 crossref_primary_10_3390_ijms20174149 crossref_primary_10_3390_diagnostics7030042 crossref_primary_10_3390_neurolint14020029 crossref_primary_10_3390_brainsci11111535 crossref_primary_10_1021_acsptsci_4c00149 crossref_primary_10_3233_JAD_150845 crossref_primary_10_1007_s12035_008_8019_y crossref_primary_10_1007_s00259_011_1882_1 crossref_primary_10_1073_pnas_0900345106 crossref_primary_10_3233_JAD_160403 crossref_primary_10_1212_WNL_0000000000000069 crossref_primary_10_1016_j_jalz_2013_12_022 crossref_primary_10_1186_alzrt96 crossref_primary_10_1093_brain_awq310 crossref_primary_10_3233_JAD_190070 crossref_primary_10_1016_j_neurol_2013_07_016 crossref_primary_10_1021_cr3000994 crossref_primary_10_2217_iim_11_34 crossref_primary_10_3233_JAD_201612 crossref_primary_10_1017_S0033291709991516 crossref_primary_10_2463_mrms_mp_2021_0123 crossref_primary_10_1007_s00259_013_2562_0 crossref_primary_10_1016_j_cpet_2017_03_001 crossref_primary_10_3390_jpm10030061 crossref_primary_10_1007_s11910_009_0051_4 crossref_primary_10_1016_S1474_4422_14_70090_0 crossref_primary_10_1126_scitranslmed_3007901 crossref_primary_10_3233_JAD_200758 crossref_primary_10_1007_s12603_009_0217_4 crossref_primary_10_1007_s00415_009_5396_8 crossref_primary_10_1186_alzrt88 crossref_primary_10_1097_YCO_0b013e32835f6747 crossref_primary_10_1016_j_remnie_2013_07_027 crossref_primary_10_37549_AR2081 crossref_primary_10_1016_j_jalz_2011_05_2243 crossref_primary_10_1016_j_pneurobio_2016_03_003 crossref_primary_10_1016_j_cej_2019_05_107 crossref_primary_10_1186_s13195_018_0445_0 crossref_primary_10_3233_JAD_200890 crossref_primary_10_1016_j_pneurobio_2010_11_005 crossref_primary_10_1016_j_neuroimage_2009_12_070 crossref_primary_10_2174_0115672050243131230925034334 crossref_primary_10_1016_j_clineuro_2020_105679 crossref_primary_10_1093_brain_awq349 crossref_primary_10_1186_alzrt70 crossref_primary_10_1586_erm_11_67 crossref_primary_10_1097_YCO_0b013e328314b763 crossref_primary_10_2217_nmt_11_11 crossref_primary_10_1016_j_jalz_2012_10_007 crossref_primary_10_1016_j_bbr_2016_05_030 crossref_primary_10_3233_JAD_170327 crossref_primary_10_1212_WNL_0b013e3181b61b5d crossref_primary_10_3390_jcm13164661 crossref_primary_10_2217_fnl_10_23 crossref_primary_10_1016_j_neurobiolaging_2017_11_005 crossref_primary_10_1007_s10072_018_3477_0 crossref_primary_10_1371_journal_pone_0058974 crossref_primary_10_1586_ern_11_45 crossref_primary_10_1016_j_jalz_2013_12_014 crossref_primary_10_1142_S1793545822300014 crossref_primary_10_1016_j_jalz_2013_12_012 crossref_primary_10_1007_s00415_011_6030_0 crossref_primary_10_1097_WCO_0b013e3283168e1a crossref_primary_10_1038_mp_2008_96 crossref_primary_10_1371_journal_pone_0066381 crossref_primary_10_1016_j_jalz_2013_04_506 crossref_primary_10_1212_WNL_0000000000012123 crossref_primary_10_4103_0972_6748_328840 crossref_primary_10_1016_j_nicl_2017_12_003 crossref_primary_10_1177_1073858410392586 crossref_primary_10_1007_BF02982592 crossref_primary_10_1002_prca_201400178 crossref_primary_10_1016_j_mrfmmm_2014_12_012 crossref_primary_10_1212_WNL_0b013e3182231419 crossref_primary_10_1007_s11071_023_08547_y crossref_primary_10_1016_j_remn_2013_06_012 crossref_primary_10_2217_bmm_2017_0433 crossref_primary_10_1074_mcp_R115_053330 crossref_primary_10_2967_jnumed_114_148981 crossref_primary_10_1007_s00259_007_0700_2 crossref_primary_10_1007_s40846_022_00717_4 crossref_primary_10_1002_jlcr_1745 crossref_primary_10_1371_journal_pone_0058752 crossref_primary_10_1053_j_semnuclmed_2012_07_001 crossref_primary_10_56951_medicinus_v33i3_70 crossref_primary_10_1155_2016_7462014 crossref_primary_10_3389_fnagi_2020_608628 crossref_primary_10_3233_JAD_170475 crossref_primary_10_1007_s11065_015_9297_6 crossref_primary_10_2217_bmm_12_47 crossref_primary_10_1016_j_neurol_2012_07_005 crossref_primary_10_1016_j_neuint_2011_10_010 crossref_primary_10_1016_S1634_7072_14_67223_8 crossref_primary_10_1016_j_biopsych_2010_02_004 crossref_primary_10_4061_2010_163065 crossref_primary_10_1016_j_mcna_2012_12_017 crossref_primary_10_1007_s00115_010_2951_6 crossref_primary_10_3389_fnagi_2018_00366 crossref_primary_10_1016_j_neuroscience_2017_07_017 crossref_primary_10_1016_j_neurobiolaging_2013_06_018 crossref_primary_10_1016_j_remnie_2015_09_005 crossref_primary_10_1007_s00521_013_1465_0 crossref_primary_10_1016_j_neubiorev_2011_06_009 crossref_primary_10_1016_j_mednuc_2008_05_002 crossref_primary_10_1212_WNL_0b013e3182661f4d crossref_primary_10_1016_j_nlm_2013_05_003 crossref_primary_10_1111_ggi_12147 crossref_primary_10_1038_nature20412 crossref_primary_10_1259_bjr_97295129 crossref_primary_10_1002_gps_3829 crossref_primary_10_1212_WNL_0b013e318212015e crossref_primary_10_1212_WNL_0b013e3182563bd0 crossref_primary_10_1016_j_pharmthera_2011_12_007 crossref_primary_10_1371_journal_pone_0035559 crossref_primary_10_1177_0891988710363715 crossref_primary_10_1177_0271678X17741395 crossref_primary_10_1016_j_apradiso_2010_07_001 crossref_primary_10_3233_JAD_150570 crossref_primary_10_1016_j_neurobiolaging_2010_04_028 crossref_primary_10_1016_j_mednuc_2015_03_192 crossref_primary_10_1093_brain_awq277 crossref_primary_10_2478_s13380_014_0205_y crossref_primary_10_1093_brain_awp062 crossref_primary_10_1007_s12149_009_0330_9 crossref_primary_10_5692_clinicalneurol_49_922 crossref_primary_10_1038_s41598_018_23676_w crossref_primary_10_2217_bmm_12_42 crossref_primary_10_1016_j_neuroimage_2015_10_026 crossref_primary_10_1155_2011_439397 crossref_primary_10_1002_alz_12184 crossref_primary_10_1016_j_maturitas_2014_02_016 crossref_primary_10_1007_s00115_018_0533_1 crossref_primary_10_3233_JAD_170035 crossref_primary_10_1590_1516_4446_2013_1275 crossref_primary_10_1038_nrneurol_2010_4 crossref_primary_10_1016_j_parkreldis_2007_07_010 crossref_primary_10_1517_17530059_2011_617365 crossref_primary_10_3233_JAD_170158 crossref_primary_10_1016_j_neurobiolaging_2009_08_006 crossref_primary_10_2217_bmm_09_80 crossref_primary_10_2217_bmm_09_83 crossref_primary_10_3389_fnagi_2017_00157 crossref_primary_10_1016_j_neuroimage_2011_11_075 crossref_primary_10_1186_1750_1326_8_20 crossref_primary_10_1016_j_advms_2014_11_002 crossref_primary_10_1016_j_exger_2011_04_001 crossref_primary_10_1016_j_jns_2009_06_005 crossref_primary_10_1212_WNL_0b013e3182872830 crossref_primary_10_1002_ana_21843 crossref_primary_10_1007_s00259_012_2102_3 crossref_primary_10_1007_s00259_014_2919_z crossref_primary_10_3389_fpsyt_2022_1039725 crossref_primary_10_1016_j_neurobiolaging_2009_08_016 crossref_primary_10_1016_j_mednuc_2011_02_007 crossref_primary_10_1002_gps_4165 crossref_primary_10_2967_jnumed_110_083683 crossref_primary_10_2217_bmm_11_48 crossref_primary_10_1093_psyrad_kkad009 crossref_primary_10_1016_j_bbadis_2011_11_006 crossref_primary_10_1186_s13195_014_0087_9 crossref_primary_10_1016_j_revmed_2010_08_006 crossref_primary_10_1016_j_jalz_2013_01_002 crossref_primary_10_1055_a_1712_6110 crossref_primary_10_61186_shefa_10_2_91 crossref_primary_10_1038_nrneurol_2013_107 crossref_primary_10_1186_s13195_022_01104_6 crossref_primary_10_1212_WNL_0b013e31825fdf18 crossref_primary_10_3233_JAD_150123 crossref_primary_10_1212_WNL_0b013e3181b23564 crossref_primary_10_1155_2016_7898093 crossref_primary_10_1007_s00259_007_0705_x crossref_primary_10_1016_j_neurobiolaging_2009_07_015 crossref_primary_10_1016_j_neurobiolaging_2010_03_011 crossref_primary_10_1002_ana_21904 crossref_primary_10_5124_jkma_2009_52_2_151 crossref_primary_10_1038_srep16404 crossref_primary_10_1016_j_jalz_2013_01_013 crossref_primary_10_1159_000356273 crossref_primary_10_1371_journal_pone_0063829 crossref_primary_10_4061_2010_606802 crossref_primary_10_1016_j_cnsns_2020_105347 crossref_primary_10_1007_s11011_021_00800_w crossref_primary_10_1002_msj_20156 crossref_primary_10_1016_j_cpet_2009_12_008 crossref_primary_10_1155_2014_785039 crossref_primary_10_2967_jnumed_113_120618 crossref_primary_10_1016_j_cpet_2009_12_003 crossref_primary_10_1007_s00259_011_2021_8 crossref_primary_10_1111_joim_12190 crossref_primary_10_2967_jnumed_109_064360 crossref_primary_10_1111_bpa_12399 crossref_primary_10_1007_s00259_015_3208_1 crossref_primary_10_1002_acn3_81 crossref_primary_10_2165_11310890_000000000_00000 crossref_primary_10_1093_brain_awq383 crossref_primary_10_1017_S1355617710000822 crossref_primary_10_1186_s12883_015_0459_1 crossref_primary_10_1021_acs_bioconjchem_7b00500 crossref_primary_10_1016_j_ejmech_2014_10_016 crossref_primary_10_1016_j_exger_2018_01_002 crossref_primary_10_1016_j_neurobiolaging_2008_05_026 crossref_primary_10_1007_s00259_010_1382_8 crossref_primary_10_1002_syn_20782 crossref_primary_10_2967_jnumed_108_058529 crossref_primary_10_1007_s00103_010_1096_x crossref_primary_10_17116_jnevro201511511172_79 crossref_primary_10_1016_j_jalz_2012_07_003 crossref_primary_10_1007_s00259_011_2045_0 crossref_primary_10_1007_s00259_014_2753_3 crossref_primary_10_1097_WCO_0b013e32832d93c7 crossref_primary_10_1186_1741_7015_10_127 crossref_primary_10_3390_ph15101191 crossref_primary_10_1016_j_neuropsychologia_2017_04_002 crossref_primary_10_1160_TH14_11_0938 crossref_primary_10_1177_1471301214562135 crossref_primary_10_1056_NEJMcp0910237 crossref_primary_10_1016_j_neuroimage_2009_06_021 crossref_primary_10_3233_JAD_180939 crossref_primary_10_3233_JAD_150049 crossref_primary_10_1002_gps_2113 crossref_primary_10_1080_21553769_2015_1044129 crossref_primary_10_1111_j_1749_6632_2009_05066_x crossref_primary_10_1038_nrneurol_2014_232 crossref_primary_10_1001_archneurol_2011_105 crossref_primary_10_1007_s12017_011_8147_9 crossref_primary_10_1093_brain_awu367 crossref_primary_10_1007_s12149_018_1292_6 crossref_primary_10_2967_jnumed_108_056499 crossref_primary_10_1007_s00702_015_1404_6 crossref_primary_10_2967_jnumed_113_120378 crossref_primary_10_1016_j_jalz_2011_07_003 crossref_primary_10_1517_17530050903133790 crossref_primary_10_1016_j_jalz_2012_09_014 crossref_primary_10_1097_RLU_0000000000000666 crossref_primary_10_1212_WNL_0b013e3181bc010c crossref_primary_10_1016_j_nicl_2021_102713 crossref_primary_10_1002_14651858_CD010386_pub2 crossref_primary_10_1016_j_nicl_2013_05_008 crossref_primary_10_1016_j_jalz_2014_02_004 crossref_primary_10_1016_j_jagp_2015_06_004 crossref_primary_10_2967_jnumed_117_204271 crossref_primary_10_1007_s00259_009_1148_3 crossref_primary_10_1093_brain_awt142 crossref_primary_10_1080_13554794_2014_979835 crossref_primary_10_1093_brain_awt146 crossref_primary_10_1002_acn3_58 crossref_primary_10_1016_j_expneurol_2009_09_024 crossref_primary_10_1007_s12603_009_0037_6 crossref_primary_10_1016_j_jalz_2007_09_002 crossref_primary_10_1007_s00330_014_3311_x crossref_primary_10_1007_s00259_012_2108_x crossref_primary_10_1016_j_phrs_2019_03_023 crossref_primary_10_1038_nrd3115 crossref_primary_10_1590_S1980_5764_2016DN1002003 crossref_primary_10_2967_jnumed_108_051946 crossref_primary_10_1186_1741_7015_8_89 crossref_primary_10_1148_radiol_13122503 crossref_primary_10_1111_j_1749_6632_2009_04944_x crossref_primary_10_1523_JNEUROSCI_5077_10_2011 crossref_primary_10_1002_14651858_CD010632_pub2 crossref_primary_10_1007_BF03256467 crossref_primary_10_1111_j_1468_1331_2012_03859_x crossref_primary_10_1111_j_1440_1819_2011_02197_x crossref_primary_10_4061_2010_610613 crossref_primary_10_2174_1567205018666210324125116 crossref_primary_10_1186_2047_9158_1_5 crossref_primary_10_1111_jnc_14635 crossref_primary_10_1016_j_ymeth_2012_03_023 crossref_primary_10_2967_jnumed_110_077164 crossref_primary_10_1148_radiol_12110433 crossref_primary_10_7555_JBR_36_20220017 crossref_primary_10_1590_S1807_59322011001300003 crossref_primary_10_1192_apt_bp_112_010462 crossref_primary_10_1590_1516_4446_2012_3505 crossref_primary_10_1016_j_jalz_2016_08_006 crossref_primary_10_1007_s00259_009_1301_z crossref_primary_10_31887_DCNS_2009_11_2_dwshineman crossref_primary_10_1007_s11604_019_00867_7 crossref_primary_10_1155_2020_3620534 crossref_primary_10_1016_j_biomaterials_2012_04_025 crossref_primary_10_1007_s00259_007_0697_6 crossref_primary_10_1007_s00415_012_6688_y crossref_primary_10_14283_jpad_2024_68 crossref_primary_10_1016_j_psc_2011_02_010 crossref_primary_10_1111_j_1471_4159_2012_07911_x crossref_primary_10_1111_j_1468_1331_2008_02275_x crossref_primary_10_1097_MNM_0b013e32833019f3 crossref_primary_10_1586_erd_09_35 crossref_primary_10_1109_TNS_2015_2417764 crossref_primary_10_1212_01_wnl_0000338622_27876_0d crossref_primary_10_1093_brain_awr044 crossref_primary_10_1016_j_jalz_2014_04_005 crossref_primary_10_1126_scitranslmed_3002609 crossref_primary_10_1136_practneurol_2019_002468 crossref_primary_10_3233_JAD_160907 crossref_primary_10_1044_2020_AJSLP_20_00007 crossref_primary_10_1007_s13311_016_0481_z crossref_primary_10_1111_j_1471_4159_2008_05861_x crossref_primary_10_1016_j_jalz_2010_12_007 crossref_primary_10_1016_j_clineuro_2018_12_016 crossref_primary_10_1016_j_neurobiolaging_2010_06_015 crossref_primary_10_1155_2014_302712 crossref_primary_10_1038_nrneurol_2009_217 crossref_primary_10_1002_acn3_741 crossref_primary_10_3389_fnhum_2017_00643 crossref_primary_10_1053_j_semnuclmed_2016_09_006 crossref_primary_10_1080_02664763_2021_1899141 crossref_primary_10_1016_j_nic_2011_11_005 crossref_primary_10_1007_s11307_016_0935_z crossref_primary_10_1016_j_neurobiolaging_2021_12_012 crossref_primary_10_1007_s00401_012_1025_1 crossref_primary_10_1186_1750_1326_5_2 crossref_primary_10_1053_j_semnuclmed_2020_12_005 crossref_primary_10_1007_s00259_012_2237_2 crossref_primary_10_1016_j_jalz_2010_06_004 crossref_primary_10_1016_j_bbr_2018_02_017 crossref_primary_10_1212_WNL_0b013e3181d3e3e9
Cites_doi	10.1016/S1474-4422(03)00530-1 10.1016/S1474-4422(06)70355-6 10.1016/S0304-3940(00)01036-3 10.1016/j.neurobiolaging.2005.07.003 10.1097/00004728-199701000-00027 10.1212/WNL.34.7.939 10.1016/j.neulet.2005.08.030 10.1001/archneur.56.3.303 10.1056/NEJMoa054625 10.1007/s00259-002-1008-x 10.1002/ana.20730 10.1212/01.wnl.0000240117.55680.0a 10.1016/0022-3956(75)90026-6 10.1212/01.WNL.0000156914.16988.56 10.1016/S0024-3205(01)01232-2 10.1021/jm030026b 10.1097/00005072-199405000-00012 10.1111/j.1365-2796.2004.01388.x 10.1136/jnnp.2004.047720 10.1111/j.1365-2796.2004.01380.x 10.1007/s00259-003-1194-1 10.1002/ana.20009 10.1007/BF00687584 10.1212/01.WNL.0000055847.17752.E6 10.1001/archneur.56.6.673 10.1212/WNL.59.7.1034 10.1097/00001756-200103260-00045 10.1016/S1053-8119(02)00026-5 10.1093/brain/awl178 10.1002/1531-8249(20010201)49:2<202::AID-ANA40>3.0.CO;2-3 10.1016/j.neuroimage.2006.05.063 10.1111/j.1467-9450.2007.00594.x 10.1001/archneur.62.5.758 10.1001/archneur.58.3.397 10.1136/jnnp.2003.015032 10.1212/01.wnl.0000228230.26044.a4 10.1038/jcbfm.1983.1 10.1097/00019442-200201000-00004 10.1001/archneur.62.11.1728 10.1007/BF02815140 10.1002/ana.20889
ContentType	Journal Article
Copyright	2007
Copyright_xml	– notice: 2007
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS DG7 DF2
DOI	10.1016/j.neurobiolaging.2007.03.029
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic SwePub SwePub Articles SWEPUB Stockholms universitet SWEPUB Uppsala universitet
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Anatomy & Physiology Psychology Medicine
EISSN	1558-1497
EndPage	1465
ExternalDocumentID	oai_swepub_ki_se_570152 oai_DiVA_org_uu_109078 oai_DiVA_org_su_17377 17499392 10_1016_j_neurobiolaging_2007_03_029 S019745800700139X 1_s2_0_S019745800700139X
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- --K --M -~X .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 29N 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABFRF ABGSF ABIVO ABJNI ABLJU ABMAC ABMZM ABOYX ABUDA ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEFWE AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGRDE AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRLJ AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HDW HMK HMO HMQ HVGLF HZ~ IHE J1W KOM LX8 M29 M2V M41 MO0 MOBAO MVM N9A O-L O9- OAUVE OD~ OKEIE OO0 OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SSB SSH SSN SSU SSY SSZ T5K WUQ Z5R ZGI ~G- AACTN AFCTW AFKWA AJOXV AMFUW RIG AADPK AAIAV ABLVK ABYKQ AFYLN AJBFU DOVZS EFLBG LCYCR AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS DG7 DF2
ID	FETCH-LOGICAL-c611t-47f3f25a253c4ee12c078acfe01efa36ed84fd9ac981f5760c3e615b0d7ae0e3
IEDL.DBID	AIKHN
ISSN	0197-4580 1558-1497
IngestDate	Mon Aug 25 03:24:37 EDT 2025 Thu Aug 21 07:04:59 EDT 2025 Thu Aug 21 06:35:06 EDT 2025 Fri Jul 11 11:57:51 EDT 2025 Thu Apr 03 06:58:05 EDT 2025 Thu Apr 24 23:09:59 EDT 2025 Tue Jul 01 03:40:27 EDT 2025 Fri Feb 23 02:27:29 EST 2024 Sun Feb 23 10:19:35 EST 2025 Tue Aug 26 16:32:22 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	10
Keywords	Mild cognitive impairment Converters PIB FDG Amyloid CSF biomarkers PET
Language	English
License	https://www.elsevier.com/tdm/userlicense/1.0
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c611t-47f3f25a253c4ee12c078acfe01efa36ed84fd9ac981f5760c3e615b0d7ae0e3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	17499392
PQID	69439692
PQPubID	23479
PageCount	10
ParticipantIDs	swepub_primary_oai_swepub_ki_se_570152 swepub_primary_oai_DiVA_org_uu_109078 swepub_primary_oai_DiVA_org_su_17377 proquest_miscellaneous_69439692 pubmed_primary_17499392 crossref_primary_10_1016_j_neurobiolaging_2007_03_029 crossref_citationtrail_10_1016_j_neurobiolaging_2007_03_029 elsevier_sciencedirect_doi_10_1016_j_neurobiolaging_2007_03_029 elsevier_clinicalkeyesjournals_1_s2_0_S019745800700139X elsevier_clinicalkey_doi_10_1016_j_neurobiolaging_2007_03_029
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2008-10-01
PublicationDateYYYYMMDD	2008-10-01
PublicationDate_xml	– month: 10 year: 2008 text: 2008-10-01 day: 01
PublicationDecade	2000
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Neurobiology of aging
PublicationTitleAlternate	Neurobiol Aging
PublicationYear	2008
Publisher	Elsevier Inc
Publisher_xml	– name: Elsevier Inc
References	Arnaiz, Almkvist, Ivnik, Tangalos, Wahlund, Winblad, Petersen (bib6) 2004; 75 Folstein, Folstein, McHugh (bib20) 1975; 12 American Psychiatric Association (bib1) 1994 Chetelat, Baron (bib12) 2003; 18 Drzezga, Lautenschlager, Siebner, Riemenschneider, Willoch, Minoshima, Schwaiger, Kurz (bib15) 2003; 30 Hansson, Zetterberg, Buchhave, Londos, Blennow, Minthon (bib22) 2006; 5 Lopresti, Klunk, Mathis, Hoge, Ziolko, Lu, Meltzer, Schimmel, Tsopelas, Dekosky, Price (bib29) 2005; 46 Vanmechelen, Vanderstichele, Davidsson, Van Kerschaver, Van Der Perre, Sjogren, Andreasen, Blennow (bib41) 2000; 285 McKhann, Drachman, Folstein, Katzman, Price, Stadlan (bib31) 1984; 34 Petersen (bib36) 2004; 256 Yamaguchi, Hirai, Morimatsu, Shoji, Nakazato (bib45) 1989; 77 Kemppainen, Aalto, Wilson, Nagren, Helin, Bruck, Oikonen, Kailajarvi, Scheinin, Viitanen, Parkkola, Rinne (bib24) 2006; 67 Kordower, Chu, Stebbins, DeKosky, Cochran, Bennett, Mufson (bib27) 2001; 49 Petersen, Smith, Waring, Ivnik, Tangalos, Kokmen (bib37) 1999; 56 Small, Kepe, Ercoli, Siddarth, Bookheimer, Miller, Lavretsky, Burggren, Cole, Vinters, Thompson, Huang, Satyamurthy, Phelps, Barrio (bib39) 2006; 355 Andreasen, Hesse, Davidsson, Minthon, Wallin, Winblad, Vanderstichele, Vanmechelen, Blennow (bib4) 1999; 56 Herukka, Hallikainen, Soininen, Pirttila (bib23) 2005; 64 Patlak, Blasberg, Fenstermacher (bib35) 1983; 3 Klunk, Engler, Nordberg, Wang, Blomqvist, Holt, Bergstrom, Savitcheva, Huang, Estrada, Ausen, Debnath, Barletta, Price, Sandell, Lopresti, Wall, Koivisto, Antoni, Mathis, Langstrom (bib25) 2004; 55 Arnaiz, Jelic, Almkvist, Wahlund, Winblad, Valind, Nordberg (bib7) 2001; 12 Blennow, Hampel (bib9) 2003; 2 Mintun, Larossa, Sheline, Dence, Lee, Mach, Klunk, Mathis, DeKosky, Morris (bib32) 2006; 67 Morris, Storandt, Miller, McKeel, Price, Rubin, Berg (bib34) 2001; 58 Andersson, Thurfjell (bib3) 1997; 21 Lezak (bib28) 1995 Fagan, Mintun, Mach, Lee, Dence, Shah, Larossa, Spinner, Klunk, Mathis, Dekosky, Morris, Holtzman (bib19) 2006; 59 Shoghi-Jadid, Small, Agdeppa, Kepe, Ercoli, Siddarth, Read, Satyamurthy, Petric, Huang, Barrio (bib38) 2002; 10 Visser, Scheltens, Verhey (bib43) 2005; 76 Ziolko, Weissfeld, Klunk, Mathis, Hoge, Lopresti, DeKosky, Price (bib46) 2006; 33 de Leon, DeSanti, Zinkowski, Mehta, Pratico, Segal, Rusinek, Li, Tsui, Saint Louis, Clark, Tarshish, Li, Lair, Javier, Rich, Lesbre, Mosconi, Reisberg, Sadowski, DeBernadis, Kerkman, Hampel, Wahlund, Davies (bib14) 2006; 27 Mathis, Wang, Holt, Huang, Debnath, Klunk (bib30) 2003; 46 Mirra, Gearing, McKeel, Crain, Hughes, van Belle, Heyman (bib33) 1994; 53 Engler, Forsberg, Almkvist, Blomquist, Larsson, Savitcheva, Wall, Ringheim, Langstrom, Nordberg (bib17) 2006; 129 Buerger, Teipel, Zinkowski, Sunderland, Andreasen, Blennow, Ewers, Debernardis, Shen, Kerkman, Du, Hampel (bib11) 2005 Verhoeff, Wilson, Takeshita, Trop, Hussey, Singh, Kung, Kung, Houle (bib42) 2004; 12 Klunk, Wang, Huang, Debnath, Holt, Mathis (bib26) 2001; 69 Chetelat, Desgranges, De La Sayette, Viader, Eustache, Baron (bib13) 2003; 60 Edison, Archer, Hinz, Hammers, Pavese, Tai, Hotton, Cutler, Fox, Kennedy, Rossor, Brooks (bib16) 2006 Bergman, Blomberg, Almkvist (bib8) 2007; 48 Blennow, Wallin, Agren, Spenger, Siegfried, Vanmechelen (bib10) 1995; 26 Storandt, Grant, Miller, Morris (bib40) 2002; 59 Winblad, Palmer, Kivipelto, Jelic, Fratiglioni, Wahlund, Nordberg, Backman, Albert, Almkvist, Arai, Basun, Blennow, de Leon, DeCarli, Erkinjuntti, Giacobini, Graff, Hardy, Jack, Jorm, Ritchie, van Duijn, Visser, Petersen (bib44) 2004; 256 Anchisi, Borroni, Franceschi, Kerrouche, Kalbe, Beuthien-Beumann, Cappa, Lenz, Ludecke, Marcone, Mielke, Ortelli, Padovani, Pelati, Pupi, Scarpini, Weisenbach, Herholz, Salmon, Holthoff, Sorbi, Fazio, Perani (bib2) 2005; 62 Archer, Edison, Brooks, Barnes, Frost, Yeatman, Fox, Rossor (bib5) 2006; 60 Engler, Lundberg, Ekbom, Nennesmo, Nilsson, Bergstrom, Tsukada, Hartvig, Langstrom (bib18) 2003; 30 Galvin, Powlishta, Wilkins, McKeel, Xiong, Grant, Storandt, Morris (bib21) 2005; 62 Shoghi-Jadid (10.1016/j.neurobiolaging.2007.03.029_bib38) 2002; 10 Hansson (10.1016/j.neurobiolaging.2007.03.029_bib22) 2006; 5 Klunk (10.1016/j.neurobiolaging.2007.03.029_bib26) 2001; 69 Lopresti (10.1016/j.neurobiolaging.2007.03.029_bib29) 2005; 46 Petersen (10.1016/j.neurobiolaging.2007.03.029_bib37) 1999; 56 Lezak (10.1016/j.neurobiolaging.2007.03.029_bib28) 1995 Andreasen (10.1016/j.neurobiolaging.2007.03.029_bib4) 1999; 56 Kemppainen (10.1016/j.neurobiolaging.2007.03.029_bib24) 2006; 67 Visser (10.1016/j.neurobiolaging.2007.03.029_bib43) 2005; 76 Yamaguchi (10.1016/j.neurobiolaging.2007.03.029_bib45) 1989; 77 Small (10.1016/j.neurobiolaging.2007.03.029_bib39) 2006; 355 Buerger (10.1016/j.neurobiolaging.2007.03.029_bib11) 2005 Edison (10.1016/j.neurobiolaging.2007.03.029_bib16) 2006 Andersson (10.1016/j.neurobiolaging.2007.03.029_bib3) 1997; 21 Kordower (10.1016/j.neurobiolaging.2007.03.029_bib27) 2001; 49 Engler (10.1016/j.neurobiolaging.2007.03.029_bib18) 2003; 30 McKhann (10.1016/j.neurobiolaging.2007.03.029_bib31) 1984; 34 Bergman (10.1016/j.neurobiolaging.2007.03.029_bib8) 2007; 48 Winblad (10.1016/j.neurobiolaging.2007.03.029_bib44) 2004; 256 Ziolko (10.1016/j.neurobiolaging.2007.03.029_bib46) 2006; 33 Arnaiz (10.1016/j.neurobiolaging.2007.03.029_bib6) 2004; 75 Vanmechelen (10.1016/j.neurobiolaging.2007.03.029_bib41) 2000; 285 Galvin (10.1016/j.neurobiolaging.2007.03.029_bib21) 2005; 62 American Psychiatric Association (10.1016/j.neurobiolaging.2007.03.029_bib1) 1994 Arnaiz (10.1016/j.neurobiolaging.2007.03.029_bib7) 2001; 12 Klunk (10.1016/j.neurobiolaging.2007.03.029_bib25) 2004; 55 Archer (10.1016/j.neurobiolaging.2007.03.029_bib5) 2006; 60 Mirra (10.1016/j.neurobiolaging.2007.03.029_bib33) 1994; 53 Folstein (10.1016/j.neurobiolaging.2007.03.029_bib20) 1975; 12 Chetelat (10.1016/j.neurobiolaging.2007.03.029_bib12) 2003; 18 Morris (10.1016/j.neurobiolaging.2007.03.029_bib34) 2001; 58 Storandt (10.1016/j.neurobiolaging.2007.03.029_bib40) 2002; 59 Petersen (10.1016/j.neurobiolaging.2007.03.029_bib36) 2004; 256 Fagan (10.1016/j.neurobiolaging.2007.03.029_bib19) 2006; 59 Patlak (10.1016/j.neurobiolaging.2007.03.029_bib35) 1983; 3 Engler (10.1016/j.neurobiolaging.2007.03.029_bib17) 2006; 129 Verhoeff (10.1016/j.neurobiolaging.2007.03.029_bib42) 2004; 12 Drzezga (10.1016/j.neurobiolaging.2007.03.029_bib15) 2003; 30 Herukka (10.1016/j.neurobiolaging.2007.03.029_bib23) 2005; 64 Mathis (10.1016/j.neurobiolaging.2007.03.029_bib30) 2003; 46 Mintun (10.1016/j.neurobiolaging.2007.03.029_bib32) 2006; 67 Anchisi (10.1016/j.neurobiolaging.2007.03.029_bib2) 2005; 62 Blennow (10.1016/j.neurobiolaging.2007.03.029_bib9) 2003; 2 Chetelat (10.1016/j.neurobiolaging.2007.03.029_bib13) 2003; 60 de Leon (10.1016/j.neurobiolaging.2007.03.029_bib14) 2006; 27 Blennow (10.1016/j.neurobiolaging.2007.03.029_bib10) 1995; 26
References_xml	– volume: 30 start-page: 1104 year: 2003 end-page: 1113 ident: bib15 article-title: Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study publication-title: Eur. J. Nucl. Med. Mol. Imaging – volume: 75 start-page: 1275 year: 2004 end-page: 1280 ident: bib6 article-title: Mild cognitive impairment: a cross-national comparison publication-title: J. Neurol. Neurosurg. Psychiatry – volume: 64 start-page: 1294 year: 2005 end-page: 1297 ident: bib23 article-title: CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment publication-title: Neurology – volume: 2 start-page: 605 year: 2003 end-page: 613 ident: bib9 article-title: CSF markers for incipient Alzheimer's disease publication-title: Lancet Neurol. – volume: 58 start-page: 397 year: 2001 end-page: 405 ident: bib34 article-title: Mild cognitive impairment represents early-stage Alzheimer disease publication-title: Arch. Neurol. – year: 1994 ident: bib1 article-title: Diagnostic and Statistical Manual of Mental Disorders – volume: 5 start-page: 228 year: 2006 end-page: 234 ident: bib22 article-title: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study publication-title: Lancet Neurol. – volume: 33 start-page: 94 year: 2006 end-page: 102 ident: bib46 article-title: Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease publication-title: Neuroimage – volume: 56 start-page: 673 year: 1999 end-page: 680 ident: bib4 article-title: Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease publication-title: Arch. Neurol. – volume: 48 start-page: 115 year: 2007 end-page: 125 ident: bib8 article-title: The importance of impaired physical health and age in normal cognitive aging publication-title: Scand. J. Psychol. – year: 2006 ident: bib16 article-title: Amyloid hypometabolism, and cognition in Alzheimer disease. An [11C]PIB and [18F]FDGPET study publication-title: Neurology – volume: 62 start-page: 1728 year: 2005 end-page: 1733 ident: bib2 article-title: Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease publication-title: Arch. Neurol. – volume: 26 start-page: 231 year: 1995 end-page: 245 ident: bib10 article-title: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? publication-title: Mol. Chem. Neuropathol. – volume: 69 start-page: 1471 year: 2001 end-page: 1484 ident: bib26 article-title: Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain publication-title: Life Sci. – volume: 56 start-page: 303 year: 1999 end-page: 308 ident: bib37 article-title: Mild cognitive impairment: clinical characterization and outcome publication-title: Arch. Neurol. – volume: 76 start-page: 1348 year: 2005 end-page: 1354 ident: bib43 article-title: Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? publication-title: J. Neurol. Neurosurg. Psychiatry – volume: 34 start-page: 939 year: 1984 end-page: 944 ident: bib31 article-title: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease publication-title: Neurology – volume: 77 start-page: 314 year: 1989 end-page: 319 ident: bib45 article-title: Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain publication-title: Acta Neuropathol. (Berl.) – volume: 21 start-page: 136 year: 1997 end-page: 144 ident: bib3 article-title: Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans publication-title: J. Comput. Assist. Tomogr. – volume: 30 start-page: 85 year: 2003 end-page: 95 ident: bib18 article-title: Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease publication-title: Eur. J. Nucl. Med. Mol. Imaging – volume: 129 start-page: 2856 year: 2006 end-page: 2866 ident: bib17 article-title: Two-year follow-up of amyloid deposition in patients with Alzheimer's disease publication-title: Brain – volume: 62 start-page: 758 year: 2005 end-page: 765 ident: bib21 article-title: Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study publication-title: Arch. Neurol. – volume: 256 start-page: 240 year: 2004 end-page: 246 ident: bib44 article-title: Mild cognitive impairment-bey ond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment publication-title: J. Intern. Med. – volume: 67 start-page: 1575 year: 2006 end-page: 1580 ident: bib24 article-title: Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease publication-title: Neurology – volume: 12 start-page: 189 year: 1975 end-page: 198 ident: bib20 article-title: Mini-mental state. A practical method for grading the cognitive state of patients for the clinician publication-title: J. Psychiatry Res. – volume: 355 start-page: 2652 year: 2006 end-page: 2663 ident: bib39 article-title: PET of brain amyloid and tau in mild cognitive impairment publication-title: N. Engl. J. Med. – volume: 60 start-page: 1374 year: 2003 end-page: 1377 ident: bib13 article-title: Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? publication-title: Neurology – volume: 49 start-page: 202 year: 2001 end-page: 213 ident: bib27 article-title: Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment publication-title: Ann. Neurol. – volume: 46 start-page: 2740 year: 2003 end-page: 2754 ident: bib30 article-title: Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents publication-title: J. Med. Chem. – volume: 10 start-page: 24 year: 2002 end-page: 35 ident: bib38 article-title: Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease publication-title: Am. J. Geriatr. Psychiatry – volume: 12 start-page: 851 year: 2001 end-page: 855 ident: bib7 article-title: Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment publication-title: Neuroreport – volume: 27 start-page: 394 year: 2006 end-page: 401 ident: bib14 article-title: Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment publication-title: Neurobiol. Aging – volume: 18 start-page: 525 year: 2003 end-page: 541 ident: bib12 article-title: Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging publication-title: Neuroimage – volume: 53 start-page: 303 year: 1994 end-page: 315 ident: bib33 article-title: Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) publication-title: J. Neuropathol. Exp. Neurol. – volume: 60 start-page: 145 year: 2006 end-page: 147 ident: bib5 article-title: Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study publication-title: Ann. Neurol. – volume: 285 start-page: 49 year: 2000 end-page: 52 ident: bib41 article-title: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization publication-title: Neurosci. Lett. – year: 1995 ident: bib28 publication-title: Neuropsychological Assessment – volume: 46 start-page: 1959 year: 2005 end-page: 1972 ident: bib29 article-title: Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis publication-title: J. Nucl. Med. – volume: 55 start-page: 306 year: 2004 end-page: 319 ident: bib25 article-title: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B publication-title: Ann Neurol. – volume: 59 start-page: 512 year: 2006 end-page: 519 ident: bib19 article-title: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans publication-title: Ann. Neurol. – volume: 59 start-page: 1034 year: 2002 end-page: 1041 ident: bib40 article-title: Rates of progression in mild cognitive impairment and early Alzheimer's disease publication-title: Neurology – volume: 67 start-page: 446 year: 2006 end-page: 452 ident: bib32 article-title: [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease publication-title: Neurology – volume: 12 start-page: 584 year: 2004 end-page: 595 ident: bib42 article-title: In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET publication-title: Am. J. Geriatr. Psychiatry – year: 2005 ident: bib11 article-title: Increased levels of CSF phosphorylated tau in apolipoprotein E varepsilon4 carriers with mild cognitive impairment publication-title: Neurosci. Lett. – volume: 3 start-page: 1 year: 1983 end-page: 7 ident: bib35 article-title: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data publication-title: J. Cereb. Blood Flow Metab. – volume: 256 start-page: 183 year: 2004 end-page: 194 ident: bib36 article-title: Mild cognitive impairment as a diagnostic entity publication-title: J. Intern. Med. – volume: 2 start-page: 605 issue: 10 year: 2003 ident: 10.1016/j.neurobiolaging.2007.03.029_bib9 article-title: CSF markers for incipient Alzheimer's disease publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(03)00530-1 – volume: 5 start-page: 228 issue: 3 year: 2006 ident: 10.1016/j.neurobiolaging.2007.03.029_bib22 article-title: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study publication-title: Lancet Neurol. doi: 10.1016/S1474-4422(06)70355-6 – volume: 285 start-page: 49 issue: 1 year: 2000 ident: 10.1016/j.neurobiolaging.2007.03.029_bib41 article-title: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization publication-title: Neurosci. Lett. doi: 10.1016/S0304-3940(00)01036-3 – volume: 27 start-page: 394 issue: 3 year: 2006 ident: 10.1016/j.neurobiolaging.2007.03.029_bib14 article-title: Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment publication-title: Neurobiol. Aging doi: 10.1016/j.neurobiolaging.2005.07.003 – volume: 21 start-page: 136 issue: 1 year: 1997 ident: 10.1016/j.neurobiolaging.2007.03.029_bib3 article-title: Implementation and validation of a fully automatic system for intra- and interindividual registration of PET brain scans publication-title: J. Comput. Assist. Tomogr. doi: 10.1097/00004728-199701000-00027 – volume: 34 start-page: 939 issue: 7 year: 1984 ident: 10.1016/j.neurobiolaging.2007.03.029_bib31 article-title: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease publication-title: Neurology doi: 10.1212/WNL.34.7.939 – year: 2005 ident: 10.1016/j.neurobiolaging.2007.03.029_bib11 article-title: Increased levels of CSF phosphorylated tau in apolipoprotein E varepsilon4 carriers with mild cognitive impairment publication-title: Neurosci. Lett. doi: 10.1016/j.neulet.2005.08.030 – volume: 56 start-page: 303 issue: 3 year: 1999 ident: 10.1016/j.neurobiolaging.2007.03.029_bib37 article-title: Mild cognitive impairment: clinical characterization and outcome publication-title: Arch. Neurol. doi: 10.1001/archneur.56.3.303 – volume: 355 start-page: 2652 issue: 25 year: 2006 ident: 10.1016/j.neurobiolaging.2007.03.029_bib39 article-title: PET of brain amyloid and tau in mild cognitive impairment publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa054625 – year: 1994 ident: 10.1016/j.neurobiolaging.2007.03.029_bib1 – volume: 30 start-page: 85 issue: 1 year: 2003 ident: 10.1016/j.neurobiolaging.2007.03.029_bib18 article-title: Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-002-1008-x – volume: 59 start-page: 512 issue: 3 year: 2006 ident: 10.1016/j.neurobiolaging.2007.03.029_bib19 article-title: Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta(42) in humans publication-title: Ann. Neurol. doi: 10.1002/ana.20730 – volume: 67 start-page: 1575 issue: 9 year: 2006 ident: 10.1016/j.neurobiolaging.2007.03.029_bib24 article-title: Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease publication-title: Neurology doi: 10.1212/01.wnl.0000240117.55680.0a – volume: 12 start-page: 189 issue: 3 year: 1975 ident: 10.1016/j.neurobiolaging.2007.03.029_bib20 article-title: Mini-mental state. A practical method for grading the cognitive state of patients for the clinician publication-title: J. Psychiatry Res. doi: 10.1016/0022-3956(75)90026-6 – volume: 64 start-page: 1294 issue: 7 year: 2005 ident: 10.1016/j.neurobiolaging.2007.03.029_bib23 article-title: CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment publication-title: Neurology doi: 10.1212/01.WNL.0000156914.16988.56 – volume: 69 start-page: 1471 issue: 13 year: 2001 ident: 10.1016/j.neurobiolaging.2007.03.029_bib26 article-title: Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain publication-title: Life Sci. doi: 10.1016/S0024-3205(01)01232-2 – volume: 46 start-page: 2740 issue: 13 year: 2003 ident: 10.1016/j.neurobiolaging.2007.03.029_bib30 article-title: Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents publication-title: J. Med. Chem. doi: 10.1021/jm030026b – volume: 53 start-page: 303 issue: 3 year: 1994 ident: 10.1016/j.neurobiolaging.2007.03.029_bib33 article-title: Interlaboratory comparison of neuropathology assessments in Alzheimer's disease: a study of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) publication-title: J. Neuropathol. Exp. Neurol. doi: 10.1097/00005072-199405000-00012 – volume: 256 start-page: 183 issue: 3 year: 2004 ident: 10.1016/j.neurobiolaging.2007.03.029_bib36 article-title: Mild cognitive impairment as a diagnostic entity publication-title: J. Intern. Med. doi: 10.1111/j.1365-2796.2004.01388.x – volume: 76 start-page: 1348 issue: 10 year: 2005 ident: 10.1016/j.neurobiolaging.2007.03.029_bib43 article-title: Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp.2004.047720 – volume: 256 start-page: 240 issue: 3 year: 2004 ident: 10.1016/j.neurobiolaging.2007.03.029_bib44 article-title: Mild cognitive impairment-bey ond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment publication-title: J. Intern. Med. doi: 10.1111/j.1365-2796.2004.01380.x – volume: 12 start-page: 584 issue: 6 year: 2004 ident: 10.1016/j.neurobiolaging.2007.03.029_bib42 article-title: In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET publication-title: Am. J. Geriatr. Psychiatry – volume: 30 start-page: 1104 issue: 8 year: 2003 ident: 10.1016/j.neurobiolaging.2007.03.029_bib15 article-title: Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study publication-title: Eur. J. Nucl. Med. Mol. Imaging doi: 10.1007/s00259-003-1194-1 – volume: 55 start-page: 306 issue: 3 year: 2004 ident: 10.1016/j.neurobiolaging.2007.03.029_bib25 article-title: Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B publication-title: Ann Neurol. doi: 10.1002/ana.20009 – volume: 77 start-page: 314 issue: 3 year: 1989 ident: 10.1016/j.neurobiolaging.2007.03.029_bib45 article-title: Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by beta protein immunostain publication-title: Acta Neuropathol. (Berl.) doi: 10.1007/BF00687584 – volume: 46 start-page: 1959 issue: 12 year: 2005 ident: 10.1016/j.neurobiolaging.2007.03.029_bib29 article-title: Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis publication-title: J. Nucl. Med. – volume: 60 start-page: 1374 issue: 8 year: 2003 ident: 10.1016/j.neurobiolaging.2007.03.029_bib13 article-title: Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? publication-title: Neurology doi: 10.1212/01.WNL.0000055847.17752.E6 – volume: 56 start-page: 673 issue: 6 year: 1999 ident: 10.1016/j.neurobiolaging.2007.03.029_bib4 article-title: Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease publication-title: Arch. Neurol. doi: 10.1001/archneur.56.6.673 – volume: 59 start-page: 1034 issue: 7 year: 2002 ident: 10.1016/j.neurobiolaging.2007.03.029_bib40 article-title: Rates of progression in mild cognitive impairment and early Alzheimer's disease publication-title: Neurology doi: 10.1212/WNL.59.7.1034 – year: 1995 ident: 10.1016/j.neurobiolaging.2007.03.029_bib28 – volume: 12 start-page: 851 issue: 4 year: 2001 ident: 10.1016/j.neurobiolaging.2007.03.029_bib7 article-title: Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment publication-title: Neuroreport doi: 10.1097/00001756-200103260-00045 – volume: 18 start-page: 525 issue: 2 year: 2003 ident: 10.1016/j.neurobiolaging.2007.03.029_bib12 article-title: Early diagnosis of Alzheimer's disease: contribution of structural neuroimaging publication-title: Neuroimage doi: 10.1016/S1053-8119(02)00026-5 – volume: 129 start-page: 2856 issue: Pt. 11 year: 2006 ident: 10.1016/j.neurobiolaging.2007.03.029_bib17 article-title: Two-year follow-up of amyloid deposition in patients with Alzheimer's disease publication-title: Brain doi: 10.1093/brain/awl178 – volume: 49 start-page: 202 issue: 2 year: 2001 ident: 10.1016/j.neurobiolaging.2007.03.029_bib27 article-title: Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment publication-title: Ann. Neurol. doi: 10.1002/1531-8249(20010201)49:2<202::AID-ANA40>3.0.CO;2-3 – volume: 33 start-page: 94 issue: 1 year: 2006 ident: 10.1016/j.neurobiolaging.2007.03.029_bib46 article-title: Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease publication-title: Neuroimage doi: 10.1016/j.neuroimage.2006.05.063 – volume: 48 start-page: 115 year: 2007 ident: 10.1016/j.neurobiolaging.2007.03.029_bib8 article-title: The importance of impaired physical health and age in normal cognitive aging publication-title: Scand. J. Psychol. doi: 10.1111/j.1467-9450.2007.00594.x – volume: 62 start-page: 758 issue: 5 year: 2005 ident: 10.1016/j.neurobiolaging.2007.03.029_bib21 article-title: Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study publication-title: Arch. Neurol. doi: 10.1001/archneur.62.5.758 – volume: 58 start-page: 397 issue: 3 year: 2001 ident: 10.1016/j.neurobiolaging.2007.03.029_bib34 article-title: Mild cognitive impairment represents early-stage Alzheimer disease publication-title: Arch. Neurol. doi: 10.1001/archneur.58.3.397 – volume: 75 start-page: 1275 issue: 9 year: 2004 ident: 10.1016/j.neurobiolaging.2007.03.029_bib6 article-title: Mild cognitive impairment: a cross-national comparison publication-title: J. Neurol. Neurosurg. Psychiatry doi: 10.1136/jnnp.2003.015032 – year: 2006 ident: 10.1016/j.neurobiolaging.2007.03.029_bib16 article-title: Amyloid hypometabolism, and cognition in Alzheimer disease. An [11C]PIB and [18F]FDGPET study publication-title: Neurology – volume: 67 start-page: 446 issue: 3 year: 2006 ident: 10.1016/j.neurobiolaging.2007.03.029_bib32 article-title: [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease publication-title: Neurology doi: 10.1212/01.wnl.0000228230.26044.a4 – volume: 3 start-page: 1 issue: 1 year: 1983 ident: 10.1016/j.neurobiolaging.2007.03.029_bib35 article-title: Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data publication-title: J. Cereb. Blood Flow Metab. doi: 10.1038/jcbfm.1983.1 – volume: 10 start-page: 24 issue: 1 year: 2002 ident: 10.1016/j.neurobiolaging.2007.03.029_bib38 article-title: Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease publication-title: Am. J. Geriatr. Psychiatry doi: 10.1097/00019442-200201000-00004 – volume: 62 start-page: 1728 issue: 11 year: 2005 ident: 10.1016/j.neurobiolaging.2007.03.029_bib2 article-title: Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease publication-title: Arch. Neurol. doi: 10.1001/archneur.62.11.1728 – volume: 26 start-page: 231 issue: 3 year: 1995 ident: 10.1016/j.neurobiolaging.2007.03.029_bib10 article-title: Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? publication-title: Mol. Chem. Neuropathol. doi: 10.1007/BF02815140 – volume: 60 start-page: 145 issue: 1 year: 2006 ident: 10.1016/j.neurobiolaging.2007.03.029_bib5 article-title: Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study publication-title: Ann. Neurol. doi: 10.1002/ana.20889
SSID	ssj0007476
Score	2.4803152
Snippet	It is of great clinical value to identify subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography (PET)... Abstract It is of great clinical value to identify subjects at a high risk of developing AD. We previously found that the amyloid positron emission tomography... mild cognitive impairment, converters, amyloid, PET, PIB, FDG, CSF biomarkers/k It is of great clinical value to identify Subjects at a high risk of developing...
SourceID	swepub proquest pubmed crossref elsevier
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1456
SubjectTerms	Aged Aged, 80 and over Aging - metabolism Aging - pathology Alzheimer Disease - diagnostic imaging Alzheimer Disease - pathology Alzheimer Disease - physiopathology Amyloid Amyloid beta-Peptides - metabolism Benzothiazoles Cerebral Cortex - diagnostic imaging Cerebral Cortex - pathology Cerebral Cortex - physiopathology Cognition Disorders - diagnostic imaging Cognition Disorders - pathology Cognition Disorders - physiopathology Converters CSF biomarkers Disease Progression FDG Female Fluorodeoxyglucose F18 Glucose - metabolism Humans Internal Medicine Male MEDICIN MEDICINE Middle Aged Mild cognitive impairment Neurology Neuropsychological Tests PET PIB Plaque, Amyloid - diagnostic imaging Plaque, Amyloid - metabolism Plaque, Amyloid - pathology Positron-Emission Tomography Predictive Value of Tests Prognosis Psychology Psykologi SAMHÄLLSVETENSKAP SOCIAL SCIENCES Socialvetenskap
Title	PET imaging of amyloid deposition in patients with mild cognitive impairment
URI	https://www.clinicalkey.com/#!/content/1-s2.0-S019745800700139X https://www.clinicalkey.es/playcontent/1-s2.0-S019745800700139X https://dx.doi.org/10.1016/j.neurobiolaging.2007.03.029 https://www.ncbi.nlm.nih.gov/pubmed/17499392 https://www.proquest.com/docview/69439692 https://urn.kb.se/resolve?urn=urn:nbn:se:su:diva-17377 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-109078 http://kipublications.ki.se/Default.aspx?queryparsed=id:117547617
Volume	29
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB71ISEuCCjQ8Cg-LL2lm9hJnBVCaFVaLa8KiQXtzXL8QIFuttrsHrjw2xknTqrSFSriFtkeJZmMx984428ABpoalWpmQnR9RZioXIW5ccXMNKIBk1CpG7Lqj2fZ5EvybpbOtuC4Owvj0iq97299euOtfcvQa3N4UZbDzwhOeJLmjrDG4ZjZNuxSNsrQtHfHb99PznqHjIg5a09NO4rvPLoFg8s0r4Y20hEeNUWBPKchO4oazLlxpbqORP-gGW2WptO7cMdjSjJuH_sebJnqPuyNK4yn5z_JIWmyPJvt8z348OlkSsp58xhkYYmcY8ReaqJNl75Fyop4ttWauG1aMi_PNenzjIg7WFku3a7iA5ienkyPJ6GvqBCqLI5XYcItszSVNGUqMSamChGCVNZEsbGSZUbnidUjqUZ5bDESiRQzCHmKSHNpIsMewk61qMw-EKpw5XPEMVJliMFYkXButUmtpJlVqgjgZac8oTzbuCt6cS66tLLv4qrqXUFMLiImUPUBpL30Rcu6cUO5V913Et3JUvSFApeHG8rzTfKm9hO7FrGoqYjENeML4HUvecV-_-HezzvDEjjF3X8bWZnFuhbZKHF2TQN41NrbpU44BqzM9QxaA-x7HGv4m_LrWCyW30S9xpGM8wBe_G3Yeu3yEdAiAjjcMM43_cArI1KOOJI-_u-3fgK3accwHD-FndVybZ4hzFsVB7B99Cs-8JP5N2AOWSE
linkProvider	Elsevier
linkToHtml	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-NIQEvCBgf4Wt-KHvLmthJnAohVI1NBboJiYL6Zjn-QIE1nZr2gRf-ds6J02qsQkO8RbZPSS5355-d8-8AepoalWpmQgx9RZioXIW5ccXMNKIBk1CpG7Lq07Ns9CX5ME2nO3DUnYVxaZU-9rcxvYnWvqXvtdm_KMv-ZwQnPElzR1jjcMz0BtxM0H2ddx7-2uR5IF7O2jPTjuA7j25Bb5Pk1ZBGOrqjpiSQZzRkh1GDOLfOU1dx6B8ko83EdHIP7npESYbtQ9-HHVM9gL1hhavp2U9yQJocz2bzfA_Gn44npJw1j0HmlsgZrtdLTbTpkrdIWRHPtVoTt0lLZuW5JussI-KOVZYLt6f4ECYnx5OjUejrKYQqi-NlmHDLLE0lTZlKjImpQnwglTVRbKxkmdF5YvVAqkEeW1yHRIoZBDxFpLk0kWGPYLeaV-YJEKpw3nO0MVJliMBYkXButUmtpJlVqgjgdac8oTzXuCt5cS66pLLv4rLqXTlMLiImUPUBpGvpi5Zz45pyb7rvJLpzpRgJBU4O15Tn2-RN7d26FrGoqYjEFdML4O1a8pL1_sO99zvDEujg7q-NrMx8VYtsgJgxG9AAHrf2ttEJx-Uqcz291gDXPY4z_F35dSjmi2-iXuFIxnkAr_42bLVy2QhoEQEcbBnnm37glREpRxRJn_73W-_D7dHkdCzG788-PoM7tOMajp_D7nKxMi8Q8C2Ll41D_wZKDlnl
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PET+imaging+of+amyloid+deposition+in+patients+with+mild+cognitive+impairment&rft.jtitle=Neurobiology+of+aging&rft.au=Forsberg%2C+Anton&rft.au=Engler%2C+Henry&rft.au=Almkvist%2C+Ove&rft.au=Blomquist%2C+Gunnar&rft.date=2008-10-01&rft.issn=0197-4580&rft.volume=29&rft.issue=10&rft.spage=1456&rft.epage=1465&rft_id=info:doi/10.1016%2Fj.neurobiolaging.2007.03.029&rft.externalDBID=ECK1-s2.0-S019745800700139X&rft.externalDocID=1_s2_0_S019745800700139X
thumbnail_m	http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01974580%2FS0197458008X00090%2Fcov150h.gif